Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early systemic inflammatory-metabolic trajectory phenotypes are associated with survival outcomes in metastatic renal cell carcinoma treated with nivolumab.

Scientific reports·2026

Same author

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Minerva urology and nephrology·2026

Same author

Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study.

European urology oncology·2026

Same author

Prognostic Role of Serum Neuron-Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

The Prostate·2026

Same author

Monogenic forms of Parkinson's disease: a Czech cohort study.

Neurologia i neurochirurgia polska·2026

Same author

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations.

The oncologist·2026

Search research articles

Related Experiment Video

Updated: Jun 14, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Non-coding transcriptome profiles in clear-cell renal cell carcinoma.

Tereza Tesarova^1,2, Ondrej Fiala^3,4, Milan Hora⁵

¹Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic. tereza.tesarova@szu.cz.

Nature Reviews. Urology

|September 6, 2024

Summary

This summary is machine-generated.

Non-coding RNAs (ncRNAs) show promise as biomarkers for clear-cell renal cell carcinoma (ccRCC), aiding in personalized treatment. Further research and clinical trials are needed for their integration into patient care.

More Related Videos

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

Nuclei Isolation from Adult Mouse Kidney for Single-Nucleus RNA-Sequencing

Nuclei Isolation from Adult Mouse Kidney for Single-Nucleus RNA-Sequencing

Published on: September 20, 2021

Related Experiment Videos

Last Updated: Jun 14, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

Nuclei Isolation from Adult Mouse Kidney for Single-Nucleus RNA-Sequencing

Nuclei Isolation from Adult Mouse Kidney for Single-Nucleus RNA-Sequencing

Published on: September 20, 2021

Area of Science:

Uro-oncology
Molecular pathology
Biomarker discovery

Background:

Clear-cell renal cell carcinoma (ccRCC) is a prevalent urological cancer with rising incidence.
Identifying molecular biomarkers is crucial for predicting treatment response and personalizing therapy in ccRCC.
Non-coding RNAs (ncRNAs) are implicated in ccRCC pathogenesis and are being investigated as potential biomarkers.

Purpose of the Study:

To identify and evaluate non-coding RNA (ncRNA) biomarkers in clear-cell renal cell carcinoma (ccRCC).
To explore the association of ncRNA biomarkers with patient prognosis, pathological characteristics, and treatment outcomes.
To assess the potential of ncRNAs for personalized therapy selection in ccRCC.

Main Methods:

RNA sequencing analysis of ccRCC tissue samples.
Identification of dysregulated ncRNAs.
Correlation analysis of ncRNA expression with clinical parameters and treatment response.

Main Results:

Several ncRNAs were identified as dysregulated in ccRCC.
These ncRNAs demonstrate potential as prognostic and predictive biomarkers.
The findings suggest a role for ncRNAs in ccRCC development and progression.

Conclusions:

Dysregulated ncRNAs hold significant potential as biomarkers for ccRCC, aiding in prognosis and treatment selection.
Clinical implementation of ncRNA biomarkers is currently limited by validation and standardization challenges.
Accelerating clinical use requires comprehensive studies and integration into clinical trials.